G. Zucchelli

Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study

Background In the TRIBE2 study, molecularly unselected and untreated mCRC patients were randomized to receive FOLFOXIRI/bevacizumab (bev) followed by the same agents after disease progres...

T. Latiano ;

E. Tamburini ;

A. Passardi ;

Sara Lonardi ;

D. Santini ;

H. Lenz ;

A. Zaniboni ;

C. Antoniotti ;

G. Aprile ;

F. Marmorino ;

R. Bordonaro ;

G. Zucchelli ;

G. Fontanini ;

F. Corti ;

M. Korn ;

V. Conca ;

R. Moretto ;

A. Falcone ;

M. Giordano ;

C. Cremolini ;

S. Lonardj ;

C. Ugolini ;

06/30/2020

O-013: Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies.

Access the abstract

Angela Buonadonna ;

Giuliana Ritorto ;

Giacomo Allegrini ;

Carlotta Antoniotti , MD, PhD;

Sara Lonardi ;

F. Marmorino ;

G. Zucchelli ;

B. Borelli ;

R. Moretto ;

A. Falcone ;

Mariaelena Casagrande ;

G. Masi ;

Sabina Murgioni ;

C. Cremolini ;

Emanuela Dell'Aquila ;

A. Zaniboni ;

Gianluca Tomasello ;

G. Aprile ;

Federica Urbano ;

Monica Ronzoni ;

Sara Manglaviti ;

07/31/2019

Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study

Background Regorafenib is a treatment option for refractory metastatic colorectal cancer (mCRC) patients. The identification of markers to predict or monitor the efficacy of regorafenib r...

F. Marmorino ;

Filippo Pietrantonio ;

A. Boccaccino ;

C. Cremolini ;

M. Antista ;

N. Zaffaroni ;

G. Zucchelli ;

A. Martinetti ;

E. Campi ;

E. Sottotetti ;

B. Borelli ;

F. Corti ;